Contineum Plunges 29% as Bristol Myers' IPF Drug Data Raises Dose-Response Doubts
CTNM is trading near its 52-week low of $8.425 (6.9% above the low) on elevated volume (9.9× avg).
Summary
Contineum shares fell 29.3% to $9.46 after Bristol Myers Squibb reported mixed Phase 3 results for its competing IPF drug admilparant. The 60 mg dose significantly slowed lung function decline, but the 120 mg dose missed statistical significance, raising questions about dose-response. William Blair said the data validates the LPAR1 mechanism and de-risks safety, but the dose-response uncertainty weighs on Contineum's lead asset PIPE-791, which is in a Phase 2 IPF trial. This follows the September failure of Contineum's partnered asset PIPE-307 in depression, adding to pipeline pressure. The stock move reflects investor concern that PIPE-791 may face similar efficacy hurdles.
At the time of this announcement, CTNM was trading at $9.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $338.8M. The 52-week trading range was $8.43 to $17.79. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.